focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Yes, yes, yes!
I expect it's due to Philip Morris' 9% increase today.
Travelling to Central Africa is expensive. These guys are not going to be slumming it like poor NGO folk in economy; they'll fly business. Internal flights if they exist are not cheap and generally infrequent. They probably have to get to the site by private jet. Nor will they be staying in some godforsaken fleabitten place (West African reference, Desmond De Silva's "Madam where are your mangoes?"); they will be staying in secure accommodation. Doing business in the two Congos is expensive and can be dangerous, although 900K is a lot for a company like AAOG.
Chief Executive stays on. Damage to revenues and profit calculated. Should be positive.
For the avoidance of doubt.
The notes to the financial statements "Cash and cash equivalents at 31 December 2018 amounted to GBP4.9 million (2017: GBP2.7 million). Financial borrowings were GBP121k (2017: GBP260k). This balance is primarily the conditional advance from the French Government for use in the development of our cancer program. No interest is payable. In January 2018, ImmuPharma successfully completed a share placing raising GBP10 million before expenses."
"In September 2018, the Company invested GBP2.0 million (2017: GBPnil) in Incanthera Limited (Incanthera) with whom it also entered discussions on a potential collaboration on the Nucant program. The Company purchased 363,637 shares in Incanthera at a price of GBP5.50 per share. This represents a holding of approximately 15% in Incanthera. The Company was also granted warrants for a further 363,637 shares at GBP5.50 per share."
The 2 million investment in Incanthera is reported in the balance sheet as a non-currrent asset which means that it is not expected to be realised within the next twelve months. It is separate from the cash.